MX363579B - Composiciones farmaceuticas y metodos. - Google Patents
Composiciones farmaceuticas y metodos.Info
- Publication number
- MX363579B MX363579B MX2014008640A MX2014008640A MX363579B MX 363579 B MX363579 B MX 363579B MX 2014008640 A MX2014008640 A MX 2014008640A MX 2014008640 A MX2014008640 A MX 2014008640A MX 363579 B MX363579 B MX 363579B
- Authority
- MX
- Mexico
- Prior art keywords
- promoter
- methods
- subject
- inhibitor
- melanin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract 8
- 229940097396 Aminopeptidase inhibitor Drugs 0.000 abstract 3
- 102000002704 Leucyl aminopeptidase Human genes 0.000 abstract 3
- 108010004098 Leucyl aminopeptidase Proteins 0.000 abstract 3
- 229940122110 Tyrosine hydroxylase inhibitor Drugs 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporcionan composiciones farmacéuticas y estuches que incluyen un inhibidor de tirosina hidroxilasa; melanina, un promotor de melanina, o una combinación de éstos; un promotor de p450 3A4; y un inhibidor de leucina aminopeptidasa. Además, se proporcionan métodos para tratar cáncer en un sujeto, los métodos comprenden administrar una cantidad efectiva de un inhibidor de tirosina hidroxilasa, un promotor de melanina, un promotor de p450 3A4, y un inhibidor de leucina aminopeptidasa al sujeto que lo necesita. Además, se proporcionan métodos para reducir la proliferación celular en un sujeto, los métodos que comprenden administrar una cantidad eficaz de un inhibidor de tirosina hidroxilasa, un promotor de melanina, un promotor de p450 3A4, y un inhibidor de leucina aminopeptidasa al sujeto que lo necesita.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261587420P | 2012-01-17 | 2012-01-17 | |
US13/371,076 US8481498B1 (en) | 2012-01-17 | 2012-02-10 | Pharmaceutical compositions and methods |
US201261702994P | 2012-09-19 | 2012-09-19 | |
PCT/US2013/021714 WO2013109610A1 (en) | 2012-01-17 | 2013-01-16 | Pharmaceutical compositions and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014008640A MX2014008640A (es) | 2015-03-09 |
MX363579B true MX363579B (es) | 2019-03-27 |
Family
ID=48799616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014008640A MX363579B (es) | 2012-01-17 | 2013-01-16 | Composiciones farmaceuticas y metodos. |
Country Status (24)
Country | Link |
---|---|
EP (2) | EP3488848A1 (es) |
JP (4) | JP6276707B2 (es) |
KR (1) | KR102172658B1 (es) |
CN (2) | CN107714684A (es) |
AU (4) | AU2013209862A1 (es) |
BR (1) | BR112014017613A2 (es) |
CA (1) | CA2862689C (es) |
CY (1) | CY1121450T1 (es) |
DK (1) | DK2804599T3 (es) |
ES (1) | ES2706070T3 (es) |
HR (1) | HRP20190046T1 (es) |
HU (1) | HUE045314T2 (es) |
IL (2) | IL233681B (es) |
IN (1) | IN2014DN06711A (es) |
LT (1) | LT2804599T (es) |
MX (1) | MX363579B (es) |
NZ (2) | NZ628757A (es) |
PH (1) | PH12014501639A1 (es) |
PL (1) | PL2804599T3 (es) |
PT (1) | PT2804599T (es) |
RS (1) | RS58538B1 (es) |
SI (1) | SI2804599T1 (es) |
WO (1) | WO2013109610A1 (es) |
ZA (1) | ZA201405611B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130183263A1 (en) | 2012-01-17 | 2013-07-18 | Steven Hoffman | Pharmaceutical compositions and methods |
US10272068B2 (en) | 2012-01-17 | 2019-04-30 | Tyme, Inc. | Pharmaceutical compositions and methods |
EP3488848A1 (en) * | 2012-01-17 | 2019-05-29 | Tyme, Inc. | Tyrosine hydroxylase inhibitors for use in treating cancer |
US10646552B2 (en) | 2012-01-17 | 2020-05-12 | Tyme, Inc. | Pharmaceutical compositions and methods |
US9724657B2 (en) * | 2013-10-22 | 2017-08-08 | Tyme, Inc. | High-speed centrifugal mixing devices and methods of use |
US9585841B2 (en) * | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
CA2968046A1 (en) * | 2014-12-23 | 2016-06-30 | Steven Hoffman | Transdermal formulations |
US9687528B2 (en) | 2014-12-23 | 2017-06-27 | Steven Hoffman | Transdermal formulations |
US20190091252A1 (en) * | 2016-03-15 | 2019-03-28 | Tyme, Inc. | Pharmaceutical compositions for the treatment of cancer |
AU2017268351A1 (en) * | 2016-05-18 | 2018-12-06 | Tyme, Inc. | Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer |
JP2019537608A (ja) * | 2016-11-15 | 2019-12-26 | タイム,インコーポレーテッド | 癌の処置のための医薬組成物および方法 |
AU2017368135A1 (en) * | 2016-11-30 | 2019-06-13 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
EP3612225A1 (en) * | 2017-04-21 | 2020-02-26 | Steven Hoffman | Compositions and methods for treating retinopathy |
US11534420B2 (en) | 2019-05-14 | 2022-12-27 | Tyme, Inc. | Compositions and methods for treating cancer |
CA3157855A1 (en) * | 2019-10-15 | 2021-04-22 | Tyme, Inc. | Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer |
US20210220312A1 (en) * | 2020-01-17 | 2021-07-22 | Tyme, Inc. | Compositions And Methods For Modulating Cancer |
US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
JP2023553011A (ja) * | 2020-12-02 | 2023-12-20 | ホフマン・テクノロジーズ・エルエルシー | 非ヒト哺乳動物においてがんを調節するための組成物および方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5073541A (en) * | 1987-11-18 | 1991-12-17 | Administrators Of The Tulane Educational Fund | Treatment of small cell lung cancer with somatostatin analogs |
DE3823735A1 (de) * | 1988-07-13 | 1989-03-02 | Ernst Hajek | Verwendung von d-leucin (rechtsdrehende (alpha)-amino-isocapronsaeure) als wirkstoff zur bekaempfung maligner tumoren des schleimhautepithels des gesamten intestinaltraktes einschliesslich pankreas und gallenblase |
US5225435A (en) | 1990-05-18 | 1993-07-06 | Yale University | Soluble melanin |
IT1291633B1 (it) * | 1997-04-22 | 1999-01-11 | Pharmaconsult S A S | Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride |
CA2321026A1 (en) * | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
EP1119252A4 (en) * | 1998-08-21 | 2004-03-03 | Childrens Medical Center | USE OF MELANIN FOR INHIBITING ANGIOGENESIS AND MACULAR DEGENERATION |
JP2002128304A (ja) | 2000-10-20 | 2002-05-09 | Nec Eng Ltd | 給紙装置 |
AU2003296176A1 (en) * | 2002-12-26 | 2004-07-22 | Ajinomoto Co., Inc. | Inhibitor for liver cancer onset and progress |
DK1700598T3 (da) * | 2005-03-11 | 2009-08-31 | Gpc Biotech Ag | Antiproliferativ kombinationsterapi med satraplatin eller JM118 og docetaxel |
US20080085874A1 (en) * | 2006-08-28 | 2008-04-10 | The Regents Of The University Of California | Small molecule potentiator of hormonal therapy for breast cancer |
JP5073541B2 (ja) | 2007-05-09 | 2012-11-14 | ルネサスエレクトロニクス株式会社 | 半導体記憶装置 |
US20100216724A1 (en) * | 2007-09-11 | 2010-08-26 | Dorian Bevec | Use of fibronectin fragment (196-203 ) as a therapeutic agent |
US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
SG184901A1 (en) * | 2010-04-16 | 2012-11-29 | Davos Life Science Pte Ltd | Synergistic interaction of at least one vitamin e component and tyrosinase inhibitors for dermatological applications |
EP3488848A1 (en) * | 2012-01-17 | 2019-05-29 | Tyme, Inc. | Tyrosine hydroxylase inhibitors for use in treating cancer |
-
2013
- 2013-01-16 EP EP18200748.4A patent/EP3488848A1/en not_active Withdrawn
- 2013-01-16 SI SI201331315T patent/SI2804599T1/sl unknown
- 2013-01-16 DK DK13738179.4T patent/DK2804599T3/en active
- 2013-01-16 CN CN201710930325.3A patent/CN107714684A/zh active Pending
- 2013-01-16 KR KR1020147022509A patent/KR102172658B1/ko active IP Right Grant
- 2013-01-16 PT PT13738179T patent/PT2804599T/pt unknown
- 2013-01-16 BR BR112014017613A patent/BR112014017613A2/pt active Search and Examination
- 2013-01-16 PL PL13738179T patent/PL2804599T3/pl unknown
- 2013-01-16 CN CN201380012724.1A patent/CN104220057B/zh active Active
- 2013-01-16 ES ES13738179T patent/ES2706070T3/es active Active
- 2013-01-16 CA CA2862689A patent/CA2862689C/en active Active
- 2013-01-16 NZ NZ628757A patent/NZ628757A/en unknown
- 2013-01-16 EP EP13738179.4A patent/EP2804599B1/en active Active
- 2013-01-16 HU HUE13738179A patent/HUE045314T2/hu unknown
- 2013-01-16 JP JP2014553363A patent/JP6276707B2/ja active Active
- 2013-01-16 NZ NZ721280A patent/NZ721280A/en unknown
- 2013-01-16 RS RS20190046A patent/RS58538B1/sr unknown
- 2013-01-16 AU AU2013209862A patent/AU2013209862A1/en not_active Abandoned
- 2013-01-16 LT LTEP13738179.4T patent/LT2804599T/lt unknown
- 2013-01-16 MX MX2014008640A patent/MX363579B/es unknown
- 2013-01-16 WO PCT/US2013/021714 patent/WO2013109610A1/en active Application Filing
-
2014
- 2014-07-17 PH PH12014501639A patent/PH12014501639A1/en unknown
- 2014-07-17 IL IL233681A patent/IL233681B/en active IP Right Grant
- 2014-07-29 ZA ZA2014/05611A patent/ZA201405611B/en unknown
- 2014-08-11 IN IN6711DEN2014 patent/IN2014DN06711A/en unknown
-
2017
- 2017-05-29 IL IL252566A patent/IL252566B/en active IP Right Grant
- 2017-12-04 JP JP2017232279A patent/JP6789916B2/ja active Active
-
2018
- 2018-05-01 AU AU2018203026A patent/AU2018203026A1/en not_active Abandoned
-
2019
- 2019-01-07 HR HRP20190046TT patent/HRP20190046T1/hr unknown
- 2019-01-15 CY CY20191100043T patent/CY1121450T1/el unknown
-
2020
- 2020-03-06 AU AU2020201683A patent/AU2020201683A1/en not_active Abandoned
- 2020-07-03 JP JP2020115412A patent/JP7095028B2/ja active Active
-
2022
- 2022-03-29 AU AU2022202113A patent/AU2022202113A1/en active Pending
- 2022-04-14 JP JP2022066761A patent/JP2022095894A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014501639A1 (en) | Pharmaceutical compositions and methods | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
MX342951B (es) | Composiciones terapeuticamente activas y su metodo de uso. | |
MY161237A (en) | Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer | |
BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
EA201101522A1 (ru) | Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10) | |
AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
SG10201903119QA (en) | Polypeptide vaccine | |
PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
DK2252322T3 (da) | Vaccinesammensætninger | |
PH12015501088A1 (en) | Dimeric compounds | |
IN2014DN06104A (es) | ||
MX2013006319A (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. | |
MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
WO2012170742A3 (en) | Treatment and prevention of cancer with hmgb1 antagonists | |
GB201316955D0 (en) | Composition comprising a diindolymethane and a retinoid to treat a skin condition | |
MX365192B (es) | Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. | |
AU2010298020A8 (en) | Combination | |
MX2012000203A (es) | Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer. | |
WO2014005153A3 (en) | Methods for treating mds1-evi1 mediated cancer | |
MX356102B (es) | Compuestos y métodos para tratar leucemia. | |
TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
MX350868B (es) | Medicamentos y metodos para tratar cancer. |